Back to top

oncology-screening: Archive

Kevin Cook

Bull of the Day: NVIDIA (NVDA)

After Computex, I raised my price target to $200 because Wall Street still has no idea what's coming

NVDANegative Net Change

Zacks Equity Research

GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review

GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.

GSKNegative Net Change JNJNegative Net Change RAPTNo Net Change ANVSPositive Net Change

Shaun Pruitt

Top Medical Stocks to Buy for Growth & Performance

The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.

HAENegative Net Change HALOPositive Net Change NBIXNegative Net Change

Zacks Equity Research

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.

CGENPositive Net Change IDYANegative Net Change ANVSPositive Net Change ALXONegative Net Change

Zacks Equity Research

Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals

Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.

RHHBYPositive Net Change MRKPositive Net Change CGENPositive Net Change ALXONegative Net Change

Kinjel Shah

Pfizer (PFE) Stock Falls in a Year: Time to Buy, Sell or Hold?

Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.

BMYPositive Net Change PFENegative Net Change BNTXNegative Net Change

Zacks Equity Research

ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.

CGENPositive Net Change ANVSPositive Net Change ALXONegative Net Change IBRXPositive Net Change